Roundtable Roundup: Challenges of Treating Myelofibrosis

Publication
Article
Peers & Perspectives in OncologyMay 2024
Volume 2
Issue 7
Pages: 7

In separate live virtual events, James K. McCloskey II, MD, and Bart L. Scott, MD, polled participants on disease symptoms and bridging therapy options for a patient with primary myelofibrosis (PMF).

CASE SUMMARY

A man aged 62 years presented to his primary care physician (PCP) with symptoms of fatigue, night sweats, and increased bruising .

Medical history: type 2 diabetes, hypercholesterolemia, and hypertension

The PCP noticed lower hemoglobin concentration (11.0-9.5 g/dL) and platelet count (350,000-195,000/μL) from a previous annual physical examination.

Two months post PCP visit, a hematologic oncologist saw him.

Examination findings: spleen 5 cm below left costal margin, fatigue and night sweats worsening, bone pain

Hemoglobin: 9.1 g/dL

Platelet count: 135,000/μL

Bone marrow fibrosis of grade 2/3, with less than 5% bone marrow blasts

Molecular analysis showed a JAK2 V617F mutation with normal karyotype and no additional mutations .

He had a history of squamous cell carcinoma of the skin .

ECOG performance status: 2

Blood: 1% blasts by manual count/flow cytometry

Diagnosis: PMF

event region maps
Poll 1
Poll 2-transplant mf
Recent Videos
Related Content